Trial Profile
A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNAHIV-PT123, NYVAC-HIV-PT1 and NYVAC-HIV-PT4, and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs DNA HIV PT123 (Primary) ; HIV gp120 vaccine (Primary) ; NYVAC-C (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 04 Jan 2017 New trial record